Using anti-poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticles

Yuan Chin Hsieh, Ta Chun Cheng, Hsin Ell Wang, Jia Je Li, Wen Wei Lin, Chien Chiao Huang, Chih Hung Chuang, Yeng Tseng Wang, Jaw Yuan Wang, Steve R. Roffler, Kuo-Hsiang Chuang, Tian Lu Cheng

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Attachment of polyethylene glycol (PEG) molecules to nanoparticles (PEGylation) is a widely-used method to improve the stability, biocompatibility and half-life of nanomedicines. However, the evaluation of the PEGylated nanomedicine pharmacokinetics (PK) requires the decomposition of particles and purification of lead compounds before analysis by high performance liquid chromatography (HPLC), mass spectrometry, etc. Therefore, a method to directly quantify un-decomposed PEGylated nanoparticles is needed. In this study, we developed anti-PEG bioparticles and combined them with anti-PEG antibodies to generate a quantitative enzyme-linked immunosorbent assay (ELISA) for direct measurement of PEGylated nanoparticles without compound purification. The anti-PEG bioparticles quantitative ELISA directly quantify PEG-quantum dots (PEG-QD), PEG-stabilizing super-paramagnetic iron oxide (PEG-SPIO), Lipo-Dox and PEGASYS and the detection limits were 0.01 nM, 0.1 nM, 15.63 ng/mL and 0.48 ng/mL, respectively. Furthermore, this anti-PEG bioparticle-based ELISA tolerated samples containing up to 10% mouse or human serum. There was no significant difference in pharmacokinetic studies of radiolabeled PEG-nanoparticles (Nano-X- 111 In) through anti-PEG bioparticle-based ELISA and a traditional gamma counter. These results suggest that the anti-PEG bioparticle-based ELISA may provide a direct and effective method for the quantitation of any whole PEGylated nanoparticles without sample preparation.

Original languageEnglish
Article number39119
JournalScientific Reports
Volume6
DOIs
Publication statusPublished - Dec 19 2016

Fingerprint

Polyethylene glycols
Nanoparticles
Immunosorbents
Assays
Medical nanotechnology
Enzymes
Pharmacokinetics
Purification
Lead compounds
High performance liquid chromatography
Biocompatibility
Semiconductor quantum dots
Mass spectrometry
Decomposition
Molecules
Antibodies

ASJC Scopus subject areas

  • General

Cite this

Hsieh, Y. C., Cheng, T. C., Wang, H. E., Li, J. J., Lin, W. W., Huang, C. C., ... Cheng, T. L. (2016). Using anti-poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticles. Scientific Reports, 6, [39119]. https://doi.org/10.1038/srep39119

Using anti-poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticles. / Hsieh, Yuan Chin; Cheng, Ta Chun; Wang, Hsin Ell; Li, Jia Je; Lin, Wen Wei; Huang, Chien Chiao; Chuang, Chih Hung; Wang, Yeng Tseng; Wang, Jaw Yuan; Roffler, Steve R.; Chuang, Kuo-Hsiang; Cheng, Tian Lu.

In: Scientific Reports, Vol. 6, 39119, 19.12.2016.

Research output: Contribution to journalArticle

Hsieh, YC, Cheng, TC, Wang, HE, Li, JJ, Lin, WW, Huang, CC, Chuang, CH, Wang, YT, Wang, JY, Roffler, SR, Chuang, K-H & Cheng, TL 2016, 'Using anti-poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticles', Scientific Reports, vol. 6, 39119. https://doi.org/10.1038/srep39119
Hsieh, Yuan Chin ; Cheng, Ta Chun ; Wang, Hsin Ell ; Li, Jia Je ; Lin, Wen Wei ; Huang, Chien Chiao ; Chuang, Chih Hung ; Wang, Yeng Tseng ; Wang, Jaw Yuan ; Roffler, Steve R. ; Chuang, Kuo-Hsiang ; Cheng, Tian Lu. / Using anti-poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticles. In: Scientific Reports. 2016 ; Vol. 6.
@article{ed4a99cb8953406bb05ccaba2a21f2f3,
title = "Using anti-poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticles",
abstract = "Attachment of polyethylene glycol (PEG) molecules to nanoparticles (PEGylation) is a widely-used method to improve the stability, biocompatibility and half-life of nanomedicines. However, the evaluation of the PEGylated nanomedicine pharmacokinetics (PK) requires the decomposition of particles and purification of lead compounds before analysis by high performance liquid chromatography (HPLC), mass spectrometry, etc. Therefore, a method to directly quantify un-decomposed PEGylated nanoparticles is needed. In this study, we developed anti-PEG bioparticles and combined them with anti-PEG antibodies to generate a quantitative enzyme-linked immunosorbent assay (ELISA) for direct measurement of PEGylated nanoparticles without compound purification. The anti-PEG bioparticles quantitative ELISA directly quantify PEG-quantum dots (PEG-QD), PEG-stabilizing super-paramagnetic iron oxide (PEG-SPIO), Lipo-Dox and PEGASYS and the detection limits were 0.01 nM, 0.1 nM, 15.63 ng/mL and 0.48 ng/mL, respectively. Furthermore, this anti-PEG bioparticle-based ELISA tolerated samples containing up to 10{\%} mouse or human serum. There was no significant difference in pharmacokinetic studies of radiolabeled PEG-nanoparticles (Nano-X- 111 In) through anti-PEG bioparticle-based ELISA and a traditional gamma counter. These results suggest that the anti-PEG bioparticle-based ELISA may provide a direct and effective method for the quantitation of any whole PEGylated nanoparticles without sample preparation.",
author = "Hsieh, {Yuan Chin} and Cheng, {Ta Chun} and Wang, {Hsin Ell} and Li, {Jia Je} and Lin, {Wen Wei} and Huang, {Chien Chiao} and Chuang, {Chih Hung} and Wang, {Yeng Tseng} and Wang, {Jaw Yuan} and Roffler, {Steve R.} and Kuo-Hsiang Chuang and Cheng, {Tian Lu}",
year = "2016",
month = "12",
day = "19",
doi = "10.1038/srep39119",
language = "English",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Using anti-poly(ethylene glycol) bioparticles for the quantitation of PEGylated nanoparticles

AU - Hsieh, Yuan Chin

AU - Cheng, Ta Chun

AU - Wang, Hsin Ell

AU - Li, Jia Je

AU - Lin, Wen Wei

AU - Huang, Chien Chiao

AU - Chuang, Chih Hung

AU - Wang, Yeng Tseng

AU - Wang, Jaw Yuan

AU - Roffler, Steve R.

AU - Chuang, Kuo-Hsiang

AU - Cheng, Tian Lu

PY - 2016/12/19

Y1 - 2016/12/19

N2 - Attachment of polyethylene glycol (PEG) molecules to nanoparticles (PEGylation) is a widely-used method to improve the stability, biocompatibility and half-life of nanomedicines. However, the evaluation of the PEGylated nanomedicine pharmacokinetics (PK) requires the decomposition of particles and purification of lead compounds before analysis by high performance liquid chromatography (HPLC), mass spectrometry, etc. Therefore, a method to directly quantify un-decomposed PEGylated nanoparticles is needed. In this study, we developed anti-PEG bioparticles and combined them with anti-PEG antibodies to generate a quantitative enzyme-linked immunosorbent assay (ELISA) for direct measurement of PEGylated nanoparticles without compound purification. The anti-PEG bioparticles quantitative ELISA directly quantify PEG-quantum dots (PEG-QD), PEG-stabilizing super-paramagnetic iron oxide (PEG-SPIO), Lipo-Dox and PEGASYS and the detection limits were 0.01 nM, 0.1 nM, 15.63 ng/mL and 0.48 ng/mL, respectively. Furthermore, this anti-PEG bioparticle-based ELISA tolerated samples containing up to 10% mouse or human serum. There was no significant difference in pharmacokinetic studies of radiolabeled PEG-nanoparticles (Nano-X- 111 In) through anti-PEG bioparticle-based ELISA and a traditional gamma counter. These results suggest that the anti-PEG bioparticle-based ELISA may provide a direct and effective method for the quantitation of any whole PEGylated nanoparticles without sample preparation.

AB - Attachment of polyethylene glycol (PEG) molecules to nanoparticles (PEGylation) is a widely-used method to improve the stability, biocompatibility and half-life of nanomedicines. However, the evaluation of the PEGylated nanomedicine pharmacokinetics (PK) requires the decomposition of particles and purification of lead compounds before analysis by high performance liquid chromatography (HPLC), mass spectrometry, etc. Therefore, a method to directly quantify un-decomposed PEGylated nanoparticles is needed. In this study, we developed anti-PEG bioparticles and combined them with anti-PEG antibodies to generate a quantitative enzyme-linked immunosorbent assay (ELISA) for direct measurement of PEGylated nanoparticles without compound purification. The anti-PEG bioparticles quantitative ELISA directly quantify PEG-quantum dots (PEG-QD), PEG-stabilizing super-paramagnetic iron oxide (PEG-SPIO), Lipo-Dox and PEGASYS and the detection limits were 0.01 nM, 0.1 nM, 15.63 ng/mL and 0.48 ng/mL, respectively. Furthermore, this anti-PEG bioparticle-based ELISA tolerated samples containing up to 10% mouse or human serum. There was no significant difference in pharmacokinetic studies of radiolabeled PEG-nanoparticles (Nano-X- 111 In) through anti-PEG bioparticle-based ELISA and a traditional gamma counter. These results suggest that the anti-PEG bioparticle-based ELISA may provide a direct and effective method for the quantitation of any whole PEGylated nanoparticles without sample preparation.

UR - http://www.scopus.com/inward/record.url?scp=85006482238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006482238&partnerID=8YFLogxK

U2 - 10.1038/srep39119

DO - 10.1038/srep39119

M3 - Article

AN - SCOPUS:85006482238

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 39119

ER -